A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation: EMBRACA subgroups by age. (October 2018) - Yerushalmi, Rinat; Eiermann, Wolfgang; Rugo, Hope; Ettl, Johannes; Hurvitz, Sara A.; Gonçalves, Anthony; Miguel, Martin; Markova, Denka; Tudor, Iulia; Blum, Joanne; Hannah, Alison; Litton, Jennifer